Building on our unique history of helping to commercialize technology out of Dartmouth College, Borealis works with academic researchers and other entrepreneurs around the world to bring healthcare innovations to market. Our healthcare portfolio comprises companies accelerating the development of life-changing therapies and improving healthcare delivery. We focus on life science platforms relating to drug discovery, delivery, and manufacturing and digital health companies that improve access and quality while lowering costs.
Compass Therapeutics, a biotechnology company committed to the ambitious goal of comprehensively drugging the human immune system, today announced that it has been named by FierceBiotech as one of 2018’s Fierce 15 biotechnology companies, designating [...]
Vets First Choice has received city approval to commence construction of a new headquarters in Portland, Maine to support its rapid growth and expansion. The new approximately 170,000 square foot facility will support more than [...]
Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, today announces that it has raised £35.5 million ($45.4 million) of new capital in a Series B financing round. Redmile Group led the [...]
Compass Therapeutics, a biotechnology company committed to the ambitious goal of comprehensively drugging the human immune system, today announced the closing of the final $49 million of its $132 million Series A financing. This financing [...]
"I’ve worked with Borealis on multiple startups, including Adimab and Compass, and can attest to the firm’s crucial role in helping Dartmouth entrepreneurs build their companies as the trusted and local early-stage investor. The Borealis team are dedicated and thoughtful partners who align themselves with founders and support their vision."
Co-Founder, Adimab and Compass Therapeutics
We’re always interested in engaging with inventors, creators, and entrepreneurs to help develop ideas and realize visions.